The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.
 
Loretta J. Nastoupil
Honoraria - ADC Therapeutics; Bristol-Myers Squibb; Caribou Biosciences; Epizyme; Genentech/Roche; Genmab; Gilead Sciences; Janssen Oncology; Morphosys; Novartis; Takeda; TG Therapeutics
Consulting or Advisory Role - Interius Biotherapeutics; SIRPant Immunotherapeutics
Research Funding - Allogene Therapeutics; Bristol-Myers Squibb/Celgene; Caribou Biosciences; Epizyme; Genentech/Roche; Gilead Sciences; IgM Biosciences; Janssen Biotech; Novartis; Takeda
Travel, Accommodations, Expenses - Genentech/Roche
 
Yuqin Song
No Relationships to Disclose
 
Laurie Helen Sehn
Honoraria - Abbvie; Amgen; AstraZeneca; BeiGene; Celgene/Bristol-Myers Squibb; Genmab; Gilead Sciences; Incyte; Janssen-Ortho; Kite, a Gilead company; Merck; Roche/Genentech; Sandoz-Novartis; Seagen; Teva
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Beigene; Celgene/Bristol-Myers Squibb; Genmab; Gilead Sciences; Incyte; Janssen; Kite, a Gilead company; Merck; Roche/Genentech; Sandoz-Novartis; Seagen; Teva; TG therapeutics
Research Funding - Roche/Genentech (Inst); Teva (Inst)
 
Clémentine Sarkozy
Honoraria - Abbvie
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Janssen
Research Funding - Roche
Expert Testimony - Incyte
Travel, Accommodations, Expenses - Incyte; Roche
 
Pier Luigi Zinzani
Consulting or Advisory Role - ADC Therapeutics; BeiGene; Bristol-Myers Squibb; Celltrion; EUSA Pharma; Gilead Sciences; Incyte; Janssen-Cilag; Kyowa Hakko Kirin; MSD; Novartis; Roche; Sandoz; Secura BIO; SERVIER; Takeda; TG Therapeutics
Speakers' Bureau - EUSA Pharma; MSD; Novartis
 
Antonio Salar Silvestre
Speakers' Bureau - BeiGene; Roche
Research Funding - Abbvie; Roche
Travel, Accommodations, Expenses - Janssen; Kite, a Gilead Company
 
Jun Zhang
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Sha Huang
Stock and Other Ownership Interests - BeiGene
 
Julie Wang
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene; Bristol-Myers Squibb
Travel, Accommodations, Expenses - BeiGene
 
Richard Delarue
Employment - BeiGene; Celgene/Bristol-Myers Squibb
Stock and Other Ownership Interests - BeiGene; Celgene/Bristol-Myers Squibb
 
Judith Trotman
Research Funding - BeiGene; Celgene/Bristol-Myers Squibb; Cellectar; Janssen; Pharmacyclics; Roche
(OPTIONAL) Uncompensated Relationships - BeiGene